Glycoprotein-Bound Sclareol Composition for Enhanced Potency

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current products containing sclareolide do not provide adequate potency, stability, and bioactivity, limiting their effectiveness in increasing cyclic adenosine monophosphate activity, which is essential for weight loss, lipolysis, and libido enhancement, due to limited availability and quality of sclareol from the clary sage plant.

Innovation Solution

A composition comprising sclareol or its derivative bound by a glycoprotein matrix, potentially produced by microorganisms like Saccharomyces cerevisiae or Lactobacillus, which enhances potency, stability, and bioactivity, allowing for effective administration as a nutritional supplement to increase cAMP activity, induce weight loss, and enhance lipolysis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If sclareolide is used in current products, then weight loss and lipolysis effects are claimed, but potency, stability and bioactivity are inadequate

Engineering Contradiction:

ImprovepotencyVSAvoidamount of sclareolide

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent combines sclareolide with a glycoprotein matrix to create a composite formulation. This composite structure enhances the potency, stability, and bioactivity of sclareolide while reducing the required amount. The glycoprotein matrix acts as a carrier that improves the pharmacological properties of the active ingredient.

Inventive Principle:

Principle #40Composite materials

Solution Approach 2:

The glycoprotein matrix serves as an intermediary substance that facilitates the absorption and action of sclareolide. This intermediate carrier enhances the bioavailability and effectiveness of sclareolide in the body, allowing for reduced dosing while maintaining or enhancing therapeutic effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Ease of manufacture

If sclareol is obtained from clary sage plant, then natural source is used, but availability is limited

Engineering Contradiction:

ImproveavailabilityVSAvoidamount of sclareol

Core Design Contradiction:

Ease of manufactureVSQuantity of substance

Solution Approach 1:

The glycoprotein matrix acts as an intermediary that enhances the bioavailability and effectiveness of sclareolide, allowing for reduced dosing while maintaining or enhancing therapeutic effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent modifies the formulation parameters by introducing a glycoprotein matrix that changes the pharmacokinetic and pharmacodynamic properties of sclareolide, improving its stability and bioactivity to achieve better therapeutic outcomes at lower doses.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If higher doses of sclareolide are used, then cAMP activity increases, but stability and bioactivity remain insufficient

Engineering Contradiction:

ImprovebioactivityVSAvoiddose amount

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

Inventive Principle:

Principle #40Composite materials

Data Source

PatentUS7588759B2Compositions comprising sclareol or derivatives thereof and uses thereof

Publication Date: 2009.09.15 AVOCA LLC

AI summary

The present invention provides a composition which includes a sclareol or a derivative thereof, wherein the sclareol or a derivative thereof is bound by a glycoprotein matrix. The composition of the invention provides improved potency, stability and bioactivity characteristics of sclareol, or its derivatives.